^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG:

    SAIL66

    i
    Other names: SAIL66, SAIL 66, SAIL-66
    Associations

    News

    Trials
    Company:
    Roche
    Drug class:
    CD3 agonist, CD137 agonist, CLDN6 inhibitor
    Related drugs:
    Associations

    News

    Trials
    1d
    CLDN6 Expression Plasticity in Ovarian Cancer: Insights into Therapeutic Optimization for CLDN6-Targeted Immunotherapy. (PubMed, Cancer Res Commun)
    Post-carboplatin analysis revealed increased CLDN6 expression, EMT-related gene changes, and enhanced T-cell infiltration, which were associated with the synergistic effect of SAIL66. Our study provides insights into the biology and plasticity of CLDN6-positive cells in EOC heterogeneity and highlights the clinical significance of CLDN6-targeting therapies for ovarian cancer treatment.
    Journal • IO biomarker
    |
    CLDN6 (Claudin 6)
    |
    carboplatin • SAIL66
    5ms
    A Phase 1 Study of SAIL66 in Patients With CLDN6-positive Locally Advanced or Metastatic Solid Tumors (clinicaltrials.gov)
    P1, N=231, Active, not recruiting, Chugai Pharmaceutical | Recruiting --> Active, not recruiting
    Enrollment closed
    |
    CLDN6 (Claudin 6)
    |
    SAIL66
    1year
    A Phase 1 Study of SAIL66 in Patients With CLDN6-positive Locally Advanced or Metastatic Solid Tumors (clinicaltrials.gov)
    P1, N=231, Recruiting, Chugai Pharmaceutical | Trial completion date: Dec 2028 --> Oct 2029 | Trial primary completion date: Dec 2028 --> Oct 2029
    Trial completion date • Trial primary completion date
    |
    CLDN6 (Claudin 6)
    |
    Gazyva (obinutuzumab) • SAIL66
    over1year
    SAIL66, a next generation CLDN6-targeting T-cell engager, demonstrates potent antitumor efficacy through dual binding to CD3/CD137. (PubMed, J Immunother Cancer)
    Our data demonstrate that SAIL66, designed to engage CLDN6, CD3, and CD137, has the potential to enhance antitumor activity and provide a potent therapeutic option for patients with ovarian and other solid tumors expressing CLDN6. Clinical trials are currently underway to evaluate the safety and efficacy of SAIL66.
    Journal • IO biomarker
    |
    CD8 (cluster of differentiation 8) • CLDN6 (Claudin 6) • CD4 (CD4 Molecule) • TNFRSF9 (TNF Receptor Superfamily Member 9)
    |
    CLDN6 expression • CLDN6 positive
    |
    SAIL66
    almost3years
    A Phase 1 Study of SAIL66 in Patients With CLDN6-positive Locally Advanced or Metastatic Solid Tumors (clinicaltrials.gov)
    P1, N=178, Recruiting, Chugai Pharmaceutical | Not yet recruiting --> Recruiting
    Enrollment open • Metastases
    |
    CLDN6 (Claudin 6)
    |
    CLDN6 positive
    |
    Actemra IV (tocilizumab) • SAIL66
    almost3years
    A Phase 1 Study of SAIL66 in Patients With CLDN6-positive Locally Advanced or Metastatic Solid Tumors (clinicaltrials.gov)
    P1, N=178, Not yet recruiting, Chugai Pharmaceutical
    New P1 trial • Metastases
    |
    CLDN6 (Claudin 6)
    |
    CLDN6 positive
    |
    Actemra IV (tocilizumab) • SAIL66